» Articles » PMID: 30214154

Inhibiting EEF-2 Kinase-mediated Autophagy Enhanced the Cytocidal Effect of AKT Inhibitor on Human Nasopharyngeal Carcinoma

Overview
Specialty Pharmacology
Date 2018 Sep 15
PMID 30214154
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Our previous research showed that AKT inactivation via small molecule inhibitors did not induce significant apoptosis, but rather markedly increased autophagy in nasopharyngeal carcinoma (NPC). The purpose of the current study was to determine whether autophagy inhibition can enhance the anticancer efficacy of an AKT inhibitor (MK-2206).

Materials And Methods: NPC cell lines CNE-2 (Epstein-Barr virus negative) and C666-1 (Epstein-Barr virus positive) were used to conduct the research. Autophagy induction effects were evaluated via Western blotting. Eukaryotic elongation factor-2 (eEF-2) kinase was specifically and stably knocked down using shRNA. The growth and proliferation of the cells were assessed by Cell Counting Kit-8. In CNE-2 xenograft tumors, the antitumor effects of an AKT inhibitor (MK-2206) combined with an eEF-2 kinase inhibitor (NH125) were tested.

Results: MK-2206 induced eEF-2 kinase-dependent autophagy in NPC cell lines. Knockdown of eEF-2 kinase using shRNA blunted the autophagy activated by MK-2206. Compared with treatment with MK-2206 alone, shRNA or NH125 suppressed eEF-2 kinase and increased the growth-inhibitory effect of MK-2206 on the human NPC cell lines. The synergistic effects of eEF-2 kinase inhibition and MK-2206 were similar to those of the combination of hydroxychloroquine and MK-2206. Moreover, NH125 showed good synergistic effects with MK-2206 in vivo.

Conclusion: eEF-2 kinase-mediated autophagy induced by AKT inhibition played a protective role in NPC cells. Inhibition of eEF-2 kinase may be an effective method for increasing the efficacy of an AKT inhibitor such as MK-2206 in NPC.

Citing Articles

Insights Into the Pathologic Roles and Regulation of Eukaryotic Elongation Factor-2 Kinase.

Ballard D, Peng H, Das J, Kumar A, Wang L, Ren Y Front Mol Biosci. 2021; 8:727863.

PMID: 34532346 PMC: 8438118. DOI: 10.3389/fmolb.2021.727863.


Progress in the Development of Eukaryotic Elongation Factor 2 Kinase (eEF2K) Natural Product and Synthetic Small Molecule Inhibitors for Cancer Chemotherapy.

Zhang B, Zou J, Zhang Q, Wang Z, Wang N, He S Int J Mol Sci. 2021; 22(5).

PMID: 33673713 PMC: 7957638. DOI: 10.3390/ijms22052408.


ELF-1 expression in nasopharyngeal carcinoma facilitates proliferation and metastasis of cancer cells via modulation of CCL2/CCR2 signaling.

Chen C, Su L, Tsai H, Hwang C Cancer Manag Res. 2019; 11:5243-5254.

PMID: 31289447 PMC: 6560358. DOI: 10.2147/CMAR.S196355.

References
1.
Ma B, Lui V, Hui C, Lau C, Wong C, Hui E . Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. Invest New Drugs. 2012; 31(3):567-75. DOI: 10.1007/s10637-012-9896-5. View

2.
Arora S, Yang J, Kinzy T, Utsumi R, Okamoto T, Kitayama T . Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res. 2003; 63(20):6894-9. View

3.
Ma B, Goh B, Lim W, Hui E, Tan E, de Lima Lopes G . Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). Invest New Drugs. 2015; 33(4):985-91. DOI: 10.1007/s10637-015-0264-0. View

4.
Hait W, Wu H, Jin S, Yang J . Elongation factor-2 kinase: its role in protein synthesis and autophagy. Autophagy. 2006; 2(4):294-6. DOI: 10.4161/auto.2857. View

5.
Kundu M, Thompson C . Macroautophagy versus mitochondrial autophagy: a question of fate?. Cell Death Differ. 2005; 12 Suppl 2:1484-9. DOI: 10.1038/sj.cdd.4401780. View